Dr Reddy’s Laboratories’ subsidiary, Aurigene Oncology Limited, received DCGI approval to conduct a phase-2 trial for India’s first novel autologous BCMA directed CAR-T cell therapy, Ribrecabtagene autoleucel, following promising phase-1 results showing significant clinical response in patients with relapsed or refractory multiple myeloma.
Related Posts
Stars are aligning for Indian bonds to extend rally into 2025
Quantum Asset Management forecasts the yield on the benchmark 10-year bond to fall as much as 50 basis points by mid-2025, while Trust Mutual Fund […]
Watch: Mukesh Ambani and Nita Ambani pay last respects to Ratan Tata
Mukesh Ambani and his family paid their last respects to Ratan Tata in Mumbai, following Tata’s demise. Tata had served as the chairman of the […]